Real-World Concordance and the Path to Clinical Validation for TROP2 NMR

This segment centers on whether TROP2 NMR, currently discussed as a research-use-only computational pathology approach, can perform reliably outside of controlled trial settings, and what steps are needed to move it toward broader clinical adoption. Dr. Santos asks about “real-world” concordance, highlighting a key practical concern: even a promising biomarker must be reproducible across laboratories, platforms, and users to be clinically meaningful.

Dr. Wistuba explains that computational biomarkers introduce added layers of complexity beyond conventional IHC. In addition to the antibody and staining protocol, deployment requires compatible autostainers, whole-slide scanning to generate digital images, and an algorithm capable of identifying tumor content and calculating an NMR score. This is why companion diagnostic-style standardization is often the initial pathway, using a defined kit, validated instrumentation, and locked analysis methods. However, he notes that real-world laboratories vary widely in equipment and workflows, making concordance studies essential.

He highlights a multicenter evaluation led by López-Ríos in Europe that tested the research-use-only methodology across 10 sites with centralized staining/scanning and distributed interpretation by ~30 pathologists using the algorithm. In this setting, concordance for classifying cases as NMR-positive versus NMR-negative was reported as extremely high (approximately 99–100%), supporting strong reproducibility when key steps are standardized. Dr. Wistuba also references additional preliminary data presented at a World Conference on Lung Cancer meeting in Barcelona, where a more decentralized workflow (local staining, scanning, and analysis) still demonstrated robust consistency, on the order of ~90% concordance, suggesting feasibility for broader implementation, albeit with some expected variability.

The conversation then shifts to what evidence is still needed. Dr. Santos emphasizes that the next critical step is prospective validation in randomized phase 3 trials to confirm that TROP2 NMR predicts outcomes and can guide treatment decisions. Dr. Wistuba adds that computational pathology biomarkers are still relatively new in thoracic oncology, and successful adoption will require careful implementation, training, and ongoing quality control as pathology transitions toward a digital future.